Avalo Therapeutics, Inc. (NASDAQ:AVTX) Short Interest Up 35.5% in March

Avalo Therapeutics, Inc. (NASDAQ:AVTX) saw a large increase in short interest during the month of March. As of March 31st, there was short interest totaling 5,542,400 shares, an increase of 35.5% from the March 15th total of 4,089,262 shares. Based on an average daily volume of 892,659 shares, the short-interest ratio is presently 6.2 days. Currently, 25.1% of the company’s stock are short sold.

Insider Buying and Selling at Avalo Therapeutics

In other news, insider Mittie Doyle sold 25,492 shares of the business’s stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $16.15, for a total transaction of $411,695.80. Following the completion of the sale, the insider owned 3,622 shares in the company, valued at approximately $58,495.30. The trade was a 87.56% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Christopher Ryan Sullivan sold 7,980 shares of the company’s stock in a transaction on Thursday, April 2nd. The shares were sold at an average price of $17.15, for a total transaction of $136,857.00. Following the completion of the transaction, the chief financial officer owned 17,338 shares of the company’s stock, valued at $297,346.70. This represents a 31.52% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 46,100 shares of company stock worth $764,724 in the last three months. 3.03% of the stock is currently owned by corporate insiders.

Institutional Trading of Avalo Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in AVTX. Orbimed Advisors LLC grew its position in Avalo Therapeutics by 39.5% during the third quarter. Orbimed Advisors LLC now owns 1,349,300 shares of the company’s stock worth $17,150,000 after buying an additional 382,300 shares during the period. Nantahala Capital Management LLC increased its holdings in Avalo Therapeutics by 24.1% during the 3rd quarter. Nantahala Capital Management LLC now owns 1,235,000 shares of the company’s stock valued at $15,697,000 after acquiring an additional 240,000 shares in the last quarter. Affinity Asset Advisors LLC raised its position in Avalo Therapeutics by 4.5% during the fourth quarter. Affinity Asset Advisors LLC now owns 1,051,054 shares of the company’s stock worth $19,087,000 after acquiring an additional 44,837 shares during the last quarter. Caligan Partners LP lifted its holdings in shares of Avalo Therapeutics by 5.8% in the fourth quarter. Caligan Partners LP now owns 881,533 shares of the company’s stock valued at $16,009,000 after purchasing an additional 48,200 shares in the last quarter. Finally, Balyasny Asset Management L.P. acquired a new stake in shares of Avalo Therapeutics in the third quarter valued at approximately $10,390,000. Institutional investors and hedge funds own 87.06% of the company’s stock.

Analyst Ratings Changes

AVTX has been the subject of a number of recent research reports. Mizuho upgraded shares of Avalo Therapeutics to a “strong-buy” rating in a research note on Thursday, December 18th. Guggenheim assumed coverage on shares of Avalo Therapeutics in a research note on Monday, February 2nd. They set a “buy” rating and a $50.00 target price for the company. HC Wainwright raised their price target on Avalo Therapeutics from $25.00 to $40.00 and gave the stock a “buy” rating in a report on Wednesday, March 25th. Wall Street Zen upgraded Avalo Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Sunday, March 29th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Avalo Therapeutics in a research report on Wednesday, April 8th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Avalo Therapeutics has an average rating of “Moderate Buy” and an average price target of $44.83.

Avalo Therapeutics Stock Up 0.6%

Shares of NASDAQ:AVTX opened at $14.51 on Friday. Avalo Therapeutics has a 52 week low of $3.39 and a 52 week high of $20.72. The company has a 50-day moving average price of $15.41 and a 200 day moving average price of $16.15. The company has a market cap of $387.62 million, a P/E ratio of -2.53 and a beta of 0.93.

Avalo Therapeutics (NASDAQ:AVTX) last issued its earnings results on Monday, March 23rd. The company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.54) by $1.17. The business had revenue of $0.06 million for the quarter, compared to analysts’ expectations of ($0.21) million. Analysts expect that Avalo Therapeutics will post -19.07 EPS for the current year.

Avalo Therapeutics Company Profile

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.